Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Immunomonitoring of Tacrolimus in Healthy Volunteers: The First Step from PK- to PD-Based Therapeutic Drug Monitoring?

In 't Veld AE, Grievink HW, Saghari M, Stuurman FE, de Kam ML, de Vries APJ, de Winter BCM, Burggraaf J, Cohen AF, Moerland M.

Int J Mol Sci. 2019 Sep 23;20(19). pii: E4710. doi: 10.3390/ijms20194710.

2.

Retinal oximetry and fractal analysis of capillary maps in sickle cell disease patients and matched healthy volunteers.

Birkhoff WAJ, van Manen L, Dijkstra J, De Kam ML, van Meurs JC, Cohen AF.

Graefes Arch Clin Exp Ophthalmol. 2019 Sep 16. doi: 10.1007/s00417-019-04458-0. [Epub ahead of print]

PMID:
31529320
3.

Effect of Food on the Pharmacokinetics of 2 Formulations of DRL-17822, a Novel Selective Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Males.

Kruithof AC, Kumar R, Stevens J, de Kam ML, Gautam A, Alikunju S, Padhi BK, Kulkarni S, Raghuvanshi RS, Gandhi R, Burggraaf J, Kamerling IMC.

Clin Pharmacol Drug Dev. 2019 Nov;8(8):1042-1052. doi: 10.1002/cpdd.707. Epub 2019 Jun 10.

PMID:
31183985
4.

No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model.

Baakman AC, Alvarez-Jimenez R, Loewen G, de Kam ML, Broekhuizen K, Hilt DC, Groeneveld GJ.

Alzheimers Dement (N Y). 2019 Apr 1;5:89-98. doi: 10.1016/j.trci.2019.02.002. eCollection 2019.

5.

Evaluation of simulated driving in comparison to laboratory-based tests to assess the pharmacodynamics of alprazolam and alcohol.

Huizinga CR, Zuiker RG, de Kam ML, Ziagkos D, Kuipers J, Mejia Y, van Gerven JM, Cohen AF.

J Psychopharmacol. 2019 Jul;33(7):791-800. doi: 10.1177/0269881119836198. Epub 2019 Mar 26.

PMID:
30912701
6.

The ultraviolet B inflammation model: Postinflammatory hyperpigmentation and validation of a reduced UVB exposure paradigm for inducing hyperalgesia in healthy subjects.

Siebenga PS, van Amerongen G, Klaassen ES, de Kam ML, Rissmann R, Groeneveld GJ.

Eur J Pain. 2019 May;23(5):874-883. doi: 10.1002/ejp.1353. Epub 2019 Feb 1.

7.

Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects.

van Esdonk MJ, Lindeman I, Okkerse P, de Kam ML, Groeneveld GJ, Stevens J.

CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):573-580. doi: 10.1002/psp4.12318. Epub 2018 Aug 13.

8.

Effect profile of paracetamol, Δ9-THC and promethazine using an evoked pain test battery in healthy subjects.

van Amerongen G, Siebenga P, de Kam ML, Hay JL, Groeneveld GJ.

Eur J Pain. 2018 Aug;22(7):1331-1342. doi: 10.1002/ejp.1222. Epub 2018 Apr 25.

PMID:
29635857
9.

Evaluating Fitness to Perform in Surgical Residents after Night Shifts and Alcohol Intoxication: The development of a "Fit-to-Perform" test.

Huizinga CRH, de Kam ML, Stockmann HBAC, van Gerven JMA, Cohen AF, van der Bogt KEA.

J Surg Educ. 2018 Jul - Aug;75(4):968-977. doi: 10.1016/j.jsurg.2018.01.010. Epub 2018 Feb 2.

PMID:
29396276
10.

Erythropoietin on cycling performance - Authors' reply.

Heuberger JAAC, Rotmans JI, Gal P, Stuurman FE, Daniels JMA, de Kam ML, Cohen AF.

Lancet Haematol. 2017 Oct;4(10):e462-e464. doi: 10.1016/S2352-3026(17)30181-3. No abstract available.

PMID:
28962681
11.

Effects of erythropoietin on cycling performance of well trained cyclists: a double-blind, randomised, placebo-controlled trial.

Heuberger JAAC, Rotmans JI, Gal P, Stuurman FE, van 't Westende J, Post TE, Daniels JMA, Moerland M, van Veldhoven PLJ, de Kam ML, Ram H, de Hon O, Posthuma JJ, Burggraaf J, Cohen AF.

Lancet Haematol. 2017 Aug;4(8):e374-e386. doi: 10.1016/S2352-3026(17)30105-9. Epub 2017 Jun 29.

PMID:
28669689
12.

Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients.

van Meir H, Nout RA, Welters MJ, Loof NM, de Kam ML, van Ham JJ, Samuels S, Kenter GG, Cohen AF, Melief CJ, Burggraaf J, van Poelgeest MI, van der Burg SH.

Oncoimmunology. 2016 Dec 23;6(2):e1267095. doi: 10.1080/2162402X.2016.1267095. eCollection 2017.

13.

The identification of patients at high risk for recurrent disease after treatment for early-stage cervical cancer.

Van Meir H, du Burck IJ, de Kam ML, Welters MJP, van der Burg SH, Trimbos JBMZ, de Kroon CD, van Poelgeest MIE.

Eur J Gynaecol Oncol. 2017;38(1):25-32.

PMID:
29767860
14.

The use of a battery of pain models to detect analgesic properties of compounds: a two-part four-way crossover study.

Okkerse P, van Amerongen G, de Kam ML, Stevens J, Butt RP, Gurrell R, Dahan A, van Gerven JM, Hay JL, Groeneveld GJ.

Br J Clin Pharmacol. 2017 May;83(5):976-990. doi: 10.1111/bcp.13183. Epub 2017 Jan 9.

15.

No evidence of potentiation of buprenorphine by milnacipran in healthy subjects using a nociceptive test battery.

Okkerse P, Alvarez-Jimenez R, Hay JL, Tehim A, Kumar R, de Kam ML, Groeneveld GJ.

Eur J Pain. 2017 Mar;21(3):494-506. doi: 10.1002/ejp.943. Epub 2016 Sep 21.

PMID:
27651026
16.

Pharmacological interactions between brivaracetam and ethanol in healthy males.

Kruithof AC, Watanabe S, Peeters PA, de Kam ML, Zuiker RG, Stevens J, van Gerven JM, Stockis A.

J Psychopharmacol. 2017 Jul;31(7):915-926. doi: 10.1177/0269881116665326. Epub 2016 Sep 20.

PMID:
27649776
17.

The effects of the nonselective benzodiazepine lorazepam and the α2 /α3 subunit-selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levels.

Te Beek ET, Chen X, Jacobs GE, Nahon KJ, de Kam ML, Lappalainen J, Cross AJ, van Gerven JM, Hay JL.

Clin Pharmacol Drug Dev. 2015 Mar;4(2):149-54. doi: 10.1002/cpdd.134. Epub 2014 Aug 28.

PMID:
27128218
18.

Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.

Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, van Poelgeest MI, Kenter GG, Kroep JR, Burggraaf J, Melief CJ, van der Burg SH.

Sci Transl Med. 2016 Apr 13;8(334):334ra52. doi: 10.1126/scitranslmed.aad8307.

PMID:
27075626
19.

Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met.

Burggraaf J, Kamerling IM, Gordon PB, Schrier L, de Kam ML, Kales AJ, Bendiksen R, Indrevoll B, Bjerke RM, Moestue SA, Yazdanfar S, Langers AM, Swaerd-Nordmo M, Torheim G, Warren MV, Morreau H, Voorneveld PW, Buckle T, van Leeuwen FW, Ødegårdstuen LI, Dalsgaard GT, Healey A, Hardwick JC.

Nat Med. 2015 Aug;21(8):955-61. doi: 10.1038/nm.3641. Epub 2015 Jul 13.

PMID:
26168295
20.

AZD6280, a novel partial γ-aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers.

Chen X, Jacobs G, de Kam ML, Jaeger J, Lappalainen J, Maruff P, Smith MA, Cross AJ, Cohen A, van Gerven J.

J Clin Psychopharmacol. 2015 Feb;35(1):22-33. doi: 10.1097/JCP.0000000000000251.

PMID:
25493397
21.

A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers.

Wisman LA, De Cock EP, Reijers JA, Kamerling IM, Van Os SH, de Kam ML, Burggraaf J, Voortman G.

Clin Drug Investig. 2014 Dec;34(12):887-94. doi: 10.1007/s40261-014-0247-5.

PMID:
25377592
22.

First proof of pharmacology in humans of a novel glucagon receptor antisense drug.

van Dongen MG, Geerts BF, Morgan ES, Brandt TA, de Kam ML, Romijn JA, Cohen AF, Bhanot S, Burggraaf J.

J Clin Pharmacol. 2015 Mar;55(3):298-306. doi: 10.1002/jcph.396. Epub 2014 Sep 15.

PMID:
25197025
23.

Changes in bone mineral density in newly diagnosed testicular cancer patients after anticancer treatment.

Willemse PM, Hamdy NA, de Kam ML, Burggraaf J, Osanto S.

J Clin Endocrinol Metab. 2014 Nov;99(11):4101-8. doi: 10.1210/jc.2014-1722. Epub 2014 Aug 13.

PMID:
25119312
24.

Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients.

Broeyer FJ, Osanto S, Suzuki J, de Jongh F, van Slooten H, Tanis BC, Bruning T, Bax JJ, Ritsema van Eck HJ, de Kam ML, Cohen AF, Mituzhima Y, Burggraaf J.

Br J Clin Pharmacol. 2014 Nov;78(5):950-60. doi: 10.1111/bcp.12429.

25.

Comparison of body surface area versus weight-based growth hormone dosing for girls with Turner syndrome.

Schrier L, de Kam ML, McKinnon R, Che Bakri A, Oostdijk W, Sas TC, Menke LA, Otten BJ, de Muinck Keizer-Schrama SM, Kristrom B, Ankarberg-Lindgren C, Burggraaf J, Albertsson-Wikland K, Wit JM.

Horm Res Paediatr. 2014;81(5):319-30. doi: 10.1159/000357844. Epub 2014 Apr 23.

26.

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.

Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N, Kamerling IM, de Kam ML, Burggraaf J, Cohen AF, Cazzola M, Calzetta L, Singh D, Spina D, Walker MJ, Page CP.

Lancet Respir Med. 2013 Nov;1(9):714-27. doi: 10.1016/S2213-2600(13)70187-5. Epub 2013 Oct 25.

PMID:
24429275
27.

Characterization of a standardized glucagon challenge test as a pharmacodynamic tool in pharmacological research.

van Dongen MG, Geerts BF, Bhanot S, Morgan ES, de Kam ML, Moerland M, Romijn JA, Cohen AF, Burggraaf J.

Horm Metab Res. 2014 Apr;46(4):269-73. doi: 10.1055/s-0033-1363223. Epub 2014 Jan 8.

PMID:
24402684
28.

Abdominal visceral and subcutaneous fat increase, insulin resistance and hyperlipidemia in testicular cancer patients treated with cisplatin-based chemotherapy.

Willemse PM, van der Meer RW, Burggraaf J, van Elderen SG, de Kam ML, de Roos A, Lamb HJ, Osanto S.

Acta Oncol. 2014 Mar;53(3):351-60. doi: 10.3109/0284186X.2013.819116. Epub 2013 Aug 19.

PMID:
23957624
29.

Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.

Klumpers LE, Fridberg M, de Kam ML, Little PB, Jensen NO, Kleinloog HD, Elling CE, van Gerven JM.

Br J Clin Pharmacol. 2013 Dec;76(6):846-57. doi: 10.1111/bcp.12141.

30.

Evaluation of a bedside device to assess the activated partial thromboplastin time for heparin monitoring in infants.

Klein RH, van der Vorst MM, de Wilde RB, Hogenbirk K, de Kam ML, Burggraaf J.

Blood Coagul Fibrinolysis. 2013 Apr;24(3):327-31. doi: 10.1097/MBC.0b013e32835d070d.

PMID:
23337708
31.

Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.

Liem-Moolenaar M, Peeters P, Kamerling IM, Hogg C, Holder G, Kleijn HJ, Spaans E, Udo De Haes J, de Kam ML, Franson KL, Cohen AF, van Gerven JM.

Br J Clin Pharmacol. 2013 Jun;75(6):1455-67. doi: 10.1111/bcp.12015.

32.

Increased impact of a contraceptive vaginal ring with ethinyl estradiol and nestorone on C-reactive protein.

Rad M, Burggraaf J, Sitruk-Ware RL, de Kam ML, Cohen AF, Kluft C.

Steroids. 2012 Nov;77(13):1483-6. doi: 10.1016/j.steroids.2012.08.003. Epub 2012 Sep 8.

PMID:
22982353
33.

A comparison of the central nervous system effects of alcohol at pseudo-steady state in Caucasian and expatriate Japanese healthy male volunteers.

Zoethout RW, de Kam ML, Dahan A, Cohen AF, van Gerven JM.

Alcohol. 2012 Nov;46(7):657-64. doi: 10.1016/j.alcohol.2012.06.004. Epub 2012 Jul 24.

PMID:
22832329
34.

Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.

Klumpers LE, Beumer TL, van Hasselt JG, Lipplaa A, Karger LB, Kleinloog HD, Freijer JI, de Kam ML, van Gerven JM.

Br J Clin Pharmacol. 2012 Jul;74(1):42-53. doi: 10.1111/j.1365-2125.2012.04164.x.

35.

Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans.

Hoch M, Hay JL, Hoever P, de Kam ML, te Beek ET, van Gerven JM, Dingemanse J.

Eur Neuropsychopharmacol. 2013 Feb;23(2):107-17. doi: 10.1016/j.euroneuro.2012.04.012. Epub 2012 May 30.

PMID:
22658401
36.

Discriminant analysis of the metabolic effects of a new combined contraceptive vaginal ring containing Nestorone/EE vs. a second-generation oral contraceptive containing levonorgestrel/EE.

Rad M, Burggraaf J, de Kam ML, Cohen AF, Kluft C.

Contraception. 2012 Sep;86(3):231-7. doi: 10.1016/j.contraception.2011.12.016. Epub 2012 Mar 23.

PMID:
22445437
37.

Hydrolyzed casein decreases postprandial glucose concentrations in T2DM patients irrespective of leucine content.

Geerts BF, van Dongen MG, Flameling B, Moerland MM, de Kam ML, Cohen AF, Romijn JA, Gerhardt CC, Kloek J, Burggraaf J.

J Diet Suppl. 2011 Sep;8(3):280-92. doi: 10.3109/19390211.2011.593617. Epub 2011 Jul 26.

PMID:
22432727
38.

Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.

te Beek ET, Moerland M, de Boer P, van Nueten L, de Kam ML, Burggraaf J, Cohen AF, van Gerven JM.

J Psychopharmacol. 2012 Aug;26(8):1119-27. doi: 10.1177/0269881111415733. Epub 2011 Sep 2.

PMID:
21890591
39.

Metabolic profile of a continuous versus a cyclic low-dose combined oral contraceptive after one year of use.

Rad M, Kluft C, de Kam ML, Meijer P, Cohen AF, Grubb GS, Constantine GD, Burggraaf J.

Eur J Contracept Reprod Health Care. 2011 Apr;16(2):85-94. doi: 10.3109/13625187.2011.556761.

PMID:
21417560
40.

Effects of morphine and alcohol on functional brain connectivity during "resting state": a placebo-controlled crossover study in healthy young men.

Khalili-Mahani N, Zoethout RM, Beckmann CF, Baerends E, de Kam ML, Soeter RP, Dahan A, van Buchem MA, van Gerven JM, Rombouts SA.

Hum Brain Mapp. 2012 May;33(5):1003-18. doi: 10.1002/hbm.21265. Epub 2011 Mar 9.

PMID:
21391283
41.

Metoclopramide as pharmacological tool to assess vasopressinergic co-activation of the hypothalamus-pituitary-adrenal (HPA) axis: a study in healthy volunteers.

Jacobs GE, Hulskotte EG, de Kam ML, Zha G, Jiang J, Hu P, Zhao Q, van Pelt J, Goekoop JG, Zitman FG, van Gerven JM.

Eur Neuropsychopharmacol. 2010 Dec;20(12):866-74. doi: 10.1016/j.euroneuro.2010.06.009. Epub 2010 Jul 23.

PMID:
20655180
42.

A pharmacological tool to assess vasopressinergic co-activation of the hypothalamus-pituitary-adrenal axis more integrally in healthy volunteers.

Jacobs GE, van Gerven JM, de Kam Ml, Elassaiss-Schaap J, Ruigt G, van Pelt J, Peeters BW, Peeters PA, Hulskotte EG.

J Psychopharmacol. 2011 Mar;25(3):361-9. doi: 10.1177/0269881109358205. Epub 2010 Feb 10.

PMID:
20147570
43.

The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.

Liem-Moolenaar M, Zoethout RW, de Boer P, Schmidt M, de Kam ML, Cohen AF, Franson KL, van Gerven JM.

J Psychopharmacol. 2010 Nov;24(11):1671-9. doi: 10.1177/0269881109106942. Epub 2010 Feb 8.

PMID:
20142308
44.

Desmopressin as a pharmacological tool in vasopressinergic hypothalamus-pituitary-adrenal axis modulation: neuroendocrine, cardiovascular and coagulatory effects.

Jacobs GE, Hulskotte EG, van Gerven JM, Zuurman L, de Kam ML, Elassaiss-Schaap J, Ruigt G, van Pelt J, Peeters BW, Peeters PA, Burggraaf J.

J Psychopharmacol. 2011 Mar;25(3):353-60. doi: 10.1177/0269881109358203. Epub 2010 Feb 8.

PMID:
20142306
45.

Central nervous system effects of haloperidol on THC in healthy male volunteers.

Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, Touw D, van Gerven JM.

J Psychopharmacol. 2010 Nov;24(11):1697-708. doi: 10.1177/0269881109358200. Epub 2010 Feb 8.

PMID:
20142302
46.

Hypothalamic glutamate levels following serotonergic stimulation: a pilot study using 7-Tesla magnetic resonance spectroscopy in healthy volunteers.

Jacobs GE, der Grond Jv, Teeuwisse WM, Langeveld TJ, van Pelt J, Verhagen JC, de Kam ML, Cohen AF, Zitman FG, van Gerven JM.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 16;34(3):486-91. doi: 10.1016/j.pnpbp.2010.01.019. Epub 2010 Feb 4.

PMID:
20138102
47.

Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers.

Zuurman L, Passier PC, de Kam ML, Kleijn HJ, Cohen AF, van Gerven JM.

J Psychopharmacol. 2010 Nov;24(11):1689-96. doi: 10.1177/0269881109106913. Epub 2009 Nov 25.

PMID:
19939872
48.

The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.

Liem-Moolenaar M, Zoethout RW, de Boer P, Schmidt M, de Kam ML, Cohen AF, Franson KL, van Gerven JM.

J Psychopharmacol. 2010 Nov;24(11):1681-7. doi: 10.1177/0269881109105573. Epub 2009 Jul 31.

PMID:
19648218
49.

Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.

Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JG, Titulaer MJ, Tjaden UR, den Hartigh J, van Gerven JM.

Clin Pharmacol Ther. 2009 Jul;86(1):44-8. doi: 10.1038/clpt.2009.35. Epub 2009 Apr 8.

PMID:
19357643
50.

Pharmacodynamics and pharmacokinetics of the novel thrombopoietin mimetic peptide RWJ-800088 in humans.

Liem-Moolenaar M, Cerneus D, Molloy CJ, End D, Brown KH, de Kam ML, Cohen AF, van Hensbergen Y, Burggraaf J.

Clin Pharmacol Ther. 2008 Oct;84(4):481-7.

PMID:
19238653

Supplemental Content

Loading ...
Support Center